| 29.6154 -0.245 (-0.82%) | 05-05 11:32 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 38.93 | 1-year : | 42.9 |
| Resists | First : | 33.33 | Second : | 36.72 |
| Pivot price | 31.02  |
|||
| Supports | First : | 27.85 | Second : | 23.17 |
| MAs | MA(5) : | 28.96 |
MA(20) : | 31.99 |
| MA(100) : | 32.9 |
MA(250) : | 29.28 |
|
| MACD | MACD : | -1 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 17.3 |
D(3) : | 12.2 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 42 | Low : | 16.78 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NAMS ] has closed above bottom band by 32.8%. Bollinger Bands are 45.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 29.93 - 30.14 | 30.14 - 30.3 |
| Low: | 27.71 - 27.93 | 27.93 - 28.09 |
| Close: | 29.57 - 29.91 | 29.91 - 30.18 |
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Sun, 03 May 2026
(NAMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Fri, 01 May 2026
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Fri, 01 May 2026
Five new hires at NewAmsterdam get stock awards covering 65,800 shares - Stock Titan
Fri, 24 Apr 2026
NewAmsterdam Pharma (NAMS) details CAO exit, bonus and equity terms - Stock Titan
Thu, 16 Apr 2026
NewAmsterdam Pharma: Cholesterol-Lowering Player Is A Risk-On Buy Today (NASDAQ:NAMS) - Seeking Alpha
Wed, 08 Apr 2026
NewAmsterdam Pharma Company (NAMS): Huge Upside Potential Grabs Attention of Billionaire Stan Druckenmiller - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 115 (M) |
| Held by Insiders | 7.147e+007 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 7,550 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.2546e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -206 % |
| Return on Assets (ttm) | 187.5 % |
| Return on Equity (ttm) | -17.3 % |
| Qtrly Rev. Growth | 2.25e+007 % |
| Gross Profit (p.s.) | -767.7 |
| Sales Per Share | -217.62 |
| EBITDA (p.s.) | 1.73077e+008 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -148 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.14 |
| Price to Cash Flow | 0.64 |
| Dividend | 0 |
| Forward Dividend | 7.68e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|